Company Overview and News

0
Elpro International to sell nearly 1.33 per cent stake in PNB MetLife

2018-05-08 thehindubusinessline
Elpro International has agreed to sell approximately 1.33 per cent shareholding in PNB MetLife India Insurance Company for a total consideration of ₹134.22 crore. The decision is subject to satisfaction of certain conditions, including approval from the Insurance Regulatory and Development Authority of India and the Competition Commission of India. Elpro International has been holding 12.75 per cent stake in PNB MetLife Insurance since 2003.
504000 ELPROINTL 512068 DECNGOLD

0
Avanti Feeds board to mull bonus, stock split

2018-05-08 thehindubusinessline
The board of Avanti Feeds will meet on Wednesday to consider proposals of sub-division of face value of equity shares and issue of bonus shares. If approved, this would be the maiden bonus issue from the food major. Shareholders will closely monitor the ratio for both stock split and bonus. Currently, the public, which include the Thai Union Group, AP Industrial Development Corporation, four alternate investment funds and some 43,000 retail investors, holds 56.
AVANTI 512068 512573 DECNGOLD

2
Eyes on Eicher Motors, Fed Bank, OBC results

2018-05-08 thehindubusinessline
Close to 40 companies will declare their quarter and year-end results for the period ended March 2018 on Wednesday.
523207 JUBILANT 500469 500403 538666 FEDA 530019 MARALOVER 533227 505200 MAGMA AHLEAST ASIANHOTNR FEDS 524000 FEDERALBNK EICHERMOT 523457 AHLWEST ECQRY 521018 LINDEINDIA KOKUYOCMLN 512068 FDBAY 533221 DECNGOLD 532774 SHARDACROP SUNDRMFAST AFL 500023

0
Biosimilar push may boost Lupin

2018-05-08 thehindubusinessline
Drug firm Lupin on Tuesday said its Japanese arm and YL Biologics have submitted a new drug application with the Japanese health regulator PMDA for marketing authorisation of a biosimilar of Etanercept used for treating rheumatoid arthritis at an affordable price.
512068 DECNGOLD

0
Tech sector gains keep world shares near one-week high

2018-05-08 thehindubusinessline
Brent futures nevertheless eased 0.8 per cent after hitting new highs above $75 a barrel and MSCI's world equity index inched a touch higher after two days of gains and having touched one-week highs in the previous session.
512068 DECNGOLD

0
European shares retreat as election woes hit Italy

2018-05-08 thehindubusinessline
European shares retreated on Tuesday amid disappointing corporate earnings and worries over a snap election in Italy that put Milan on track for its worst day since an inconclusive March general election.
512068 DECNGOLD

0
MFs log Rs 1.4 lakh cr inflows in April

2018-05-08 thehindubusinessline
Overall, investors have poured in Rs 1.4 lakh crore in mutual fund schemes last month compared with redemptions of Rs 50,752 crore in March due to long-term equity gains tax.
512068 DECNGOLD

16
Exide shares extend gains on robust net profit

2018-05-08 thehindubusinessline
Goldman Sachs has raised its FY19-20 revenue estimates by an average of 2.4 per cent to factor in robust volumes and lead prices.
EXIDEIND DB MS.PRE 512068 MS.PRF MS.PRG MS.PRA DECNGOLD EXQDY MS.PRI MS.PRK MS 500086

0
TCNS Clothing gets SEBI approval for IPO

2018-05-08 thehindubusinessline
Women’s apparel maker TCNS Clothing Company has received the markets regulator SEBI’s go-ahead to float an initial public offering. TCNS sells its products under the W, Aurelia and Wishful brands. The firm had filed draft papers with the regulator in February and obtained its “observations” on May 4, according to the latest update with the Securities and Exchange Board of India.
512068 DECNGOLD

0
Anarock, ANB Capital to start investment banking advisory service

2018-05-08 thehindubusinessline
Anarock Property Consultants today announced the merger of ANB Capital with itself to start a real estate investment banking advisory service.
512068 DECNGOLD

0
Deccan Gold Mines rallies over 17%

2018-05-08 thehindubusinessline
Shares of Deccan Gold Mines rallied as much as 17.3 per cent on hopes of a positive verdict from the Supreme Court on Hutti gold mines.
512068 DECNGOLD

0
Will Deccan Gold glitter on apex court verdict?

2018-05-07 thehindubusinessline
Shares of Deccan Gold Mines will remain in focus on Tuesday, as the Supreme Court will pronounce a verdict on Hutti gold mines. The company’s Hutti-Maski belt project, which hosts the Hutti gold deposit, is under dispute with Hutti Gold Mines Company to retain its legal rights for mining. If the Deccan Gold Mines gets an unfavourable verdict from the apex court, the stock will crash as it has rose sharply in the last few days.
512068 DECNGOLD

0
Company news: Deccan Exploration Services

2018-04-30 thehindubusinessline
Deccan Exploration Services Private Ltd, a subsidiary of Deccan Gold Mines, has paid ₹682 crore (inclusive of 10 per cent of processing fee) to Karnataka Industrial Areas Development Board (KIADB).
512068 DECNGOLD

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

13h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...